Last $8.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
TBGNF On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TBGNF) Snapshot

Open
$8.50
Previous Close
$8.50
Day High
$8.50
Day Low
$8.50
52 Week High
05/6/14 - $32.85
52 Week Low
12/16/14 - $7.56
Market Cap
306.8M
Average Volume 10 Days
111.8
EPS TTM
--
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THROMBOGENICS NV (TBGNF)

Related News

No related news articles were found.

thrombogenics nv (TBGNF) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TBGNF) Details

ThromboGenics NV, an integrated biopharmaceutical company, is engaged in developing and commercializing ophthalmic and oncology medicines in Belgium and interntionally. The company offers JETREA for the treatment of symptomatic vitreomacular traction. It has a collaboration agreement with BioInvent International AB to develop anti-factor VIII, an anti-coagulation treatment for various indications, such as the prevention and treatment of deep vein thrombosis, and the treatment of atrial fibrillation; and anti-placental growth factor, an anti-angiogenic component for the treatment of various disorders, including cancer, age-related macula degeneration, retinopathy, and inflammation. The company also has a research and license agreement with Bharat Biotech; a production agreement with Fujifilm Diosynth Biotechnologies UK Limited; a license agreement Grifols and NuVue Technologies, Inc.; a life sciences research partnership with VZW; agreements with Eleven Biotherapeutics, Bicycle Therapeutics, and Flanders Institute for Biotechnology; and cooperation agreements with Centrum voor Moleculaire en Vasculaire Biologie and KULeuven. ThromboGenics NV was founded in 1991 and is headquartered in Leuven, Belgium.

154 Employees
Last Reported Date: 04/9/14
Founded in 1991

thrombogenics nv (TBGNF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €448.0K
Compensation as of Fiscal Year 2013.

thrombogenics nv (TBGNF) Key Developments

ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA

ThromboGenics NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for a new ready-diluted formulation of JETREA® (ocriplasmin). JETREA® is approved in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. VMT is an age-related progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness. The introduction of the new formulation of JETREA® will eliminate the preparatory dilution steps prior to injection. At the point of administration into the eye, the strength, potency, composition and pharmaceutical form of the ready-diluted formulation remain identical to the currently available formulation after dilution. ThromboGenics' partner Alcon, who is commercializing JETREA® outside the US, will be responsible for planning the launch of the new ready-diluted formulation.

ThromboGenics NV Nominates Emmanuele Attout as Independent Non-Executive Director

ThromboGenics NV announced that its Board of Directors has nominated Emmanuele Attout to be its new Independent non-executive director. Mrs. Attout will join the Audit Committee of the company. Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of audits of a range of clients including banks, insurance companies, investment funds and assets managers. She has in recent years been in charge of the audits of listed pharmaceuticals companies and life sciences business out of which she brings substantial relevant experience to the Board and to the Audit Committee.

ThromboGenics NV Appoints Dominique Vanfleteren as New Chief Financial Officer

ThromboGenics NV announced the appointment of Dominique Vanfleteren as its new Chief Financial Officer (CFO) with immediate effect. Dominique Vanfleteren has over 25 years of experience in senior finance, operational, control and reporting roles within quoted international biopharmaceutical companies. Before joining ThromboGenics, Dominique spent 12 years at UCB, a global biopharmaceutical company, where he held a number of international managerial finance positions, the latest being the CFO of UCB's Asia Pacific Operations, operating from Brussels and Shanghai. Prior to joining UCB, Dominique worked for GSK during 16 years. He held a number of senior finance positions in Brussels and London, his latest being Finance Director of GSK's Diversified Healthcare Services Europe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBGNF:US $8.50 USD 0.00

TBGNF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TBGNF.
View Industry Companies
 

Industry Analysis

TBGNF

Industry Average

Valuation TBGNF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.4x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.